13 completed, 13 recruiting, 10 active not recruiting, 10 terminated. 61 Phase 2, 10 Phase 1, 2 Phase 3.
Follow SABR: new trials by email Literature Review of SABR trials Research Report on SABR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer Biospecimen Collection, Computed Tomography, Lymph Node Biopsy - Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 200 | 2026-09-01 | 2026-08-26 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma axitinib plus toripalimab, SABR - Oligometastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 48 | 2026-08-15 | 2026-08-04 |
| Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide - Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 107 | 2025-12-12 | 2026-09-17 |
| Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer Stereotactic Body Radiation Therapy (SBRT) - Prostate CA | Phase 2 | Recruiting | British Columbia Cancer Agency | 100 | 2025-09-04 | 2026-06-24 |
| Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer Serplulimab, Chemotherapy, SABR - Advanced Colorectal Carcinoma, Immunotherapy | Phase 2 | Recruiting | Fudan University | 208 | 2025-03-01 | 2025-03-14 |
| Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma Biospecimen Collection, Computed Tomography, Osimertinib - Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 32 | 2024-10-21 | 2026-10-28 |
| Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) Pembrolizumab, Folfirinox, SABR - Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Amsterdam UMC, location VUmc | 66 | 2024-09-23 | 2026-02-13 |
| Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 18 | 2024-07-23 | 2026-10-07 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy High-dose Radiotherapy (HDRT), Low-dose Radiotherapy (LDRT), Anti-PD-1 monoclonal antibody - Renal Cell Carcinoma, Radiotherapy | Phase 2 | Recruiting | Jinling Hospital, China | 35 | 2023-12-15 | 2025-09-03 |
| Y-90 Versus SBRT for Inoperable HCC Quality of Life, Questionnaire Administration, Stereotactic Body Radiation Therapy - Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8 | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2023-12-01 | 2023-03-23 | |
| Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm | Phase 2 | Recruiting | City of Hope Medical Center | 32 | 2023-11-29 | 2026-08-31 |
| Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer Chemotherapy, Stereotactic Body Radiation Therapy, Computed Tomography - Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 2 | Terminated | Mayo Clinic | 2 | 2023-07-18 | 2026-06-18 |
| Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2022-11-22 | 2025-08-17 |
| 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 93 | 2022-09-02 | 2026-05-26 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study Biospecimen Collection, Bone Scan, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | NRG Oncology | 194 | 2022-04-20 | 2026-08-17 |
| NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma Pembrolizumab, Stereotactic Ablative Radiotherapy, Nephrectomy - Renal Cell Carcinoma, Clear Cell, Somatic | Phase 2 | Unknown | Peter MacCallum Cancer Centre, Australia | 20 | 2022-02-08 | 2024-05-16 |
| Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) Sintilimab, SBRT, Platinum based chemotherapy - Head and Neck Squamous Cell Carcinoma, Metastases | Phase 2 | Unknown | Jun-Lin Yi, MD | 50 | 2021-12-01 | 2021-11-29 |
| Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy Hormone Therapy, Stereotactic Body Radiation Therapy - Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8 | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 165 | 2021-06-23 | 2026-07-17 |
Showing 20 of 61. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (11) · Prostatic Neoplasms (8) · Carcinoma, Renal Cell (7) · Lung Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (6) · Neoplasm Metastasis (5) · Breast Neoplasms (3) · Adenocarcinoma of Lung (2) · Carcinoma, Hepatocellular (2) · Liver Neoplasms (2) · Melanoma (2) · Pancreatic Neoplasms (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adrenal Gland Neoplasms (1)
M.D. Anderson Cancer Center (11) · Jonsson Comprehensive Cancer Center (6) · University of Texas Southwestern Medical Center (5) · City of Hope Medical Center (4) · University of Washington (3) · Amsterdam UMC, location VUmc (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · Peter MacCallum Cancer Centre, Australia (2) · Roswell Park Cancer Institute (2) · British Columbia Cancer Agency (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Crozer-Keystone Health System (1) · David Büchser (1)
United States (40) · China (6) · Australia (4) · Canada (3) · France (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Italy (1) · Netherlands (1) · Saudi Arabia (1) · Switzerland (1)
Amar Kishan (3) · James Welsh (3) · Raquibul Hannan, MD, PhD (3) · Amar Kishan, MD (2) · Arya Amini (2) · Chad Tang (2) · Shankar Siva, A/Prof (2) · A.J. de Langen, MD, PhD (1) · Abraham Alexander (1) · Alejandro Sanchez (1) · Alfonso Gomez-Iturriaga, MD, PhD (1) · Anurag K Singh (1) · Bertrand Routy, MD PhD (1) · Bridget F Koontz (1) · Chi Lin, MD, PhD (1)
PMID 24563870, PMID 26095785, PMID 29852037, PMID 30352550, PMID 31996395, PMID 33051340, PMID 33096027, PMID 33720067, PMID 34717797, PMID 34749885, PMID 34903471, PMID 36934894, PMID 37123045, PMID 37478883, PMID 38423047, PMID 38494380, PMID 38519913, PMID 39384194, PMID 40097400, PMID 40372727, PMID 40915303, PMID 40950337, PMID 41054436, PMID 41223345, PMID 42032732, PMID 42117295, PMID 42144018, PMID 42144019, PMID 42649154
P30CA033572 (3), U10CA180821 (2), 2015 (1), 2023 (1), P30CA015704 (1), P30CA016672 (1), P30CA036727 (1), R01CA286127 (1), R01CA300454 (1), U10CA180868 (1)